Reading this on a mobile device? Try our optimized mobile version here:

December 6, 2012News for the transfusion medicine and cellular therapy community

  Top Story 
  • Team IDs genetic variations that influence red blood cells
    Australian researchers identified 75 positions on the genome that play roles in the development and function of red blood cells. The researchers analyzed study results involving 2.6 million genetic variants. The findings, published in the journal Nature, are expected to aid in research on anemia and other blood conditions. ABC (Australia) (12/6) LinkedInFacebookTwitterEmail this Story
Quotient is on a roll with new FDA approvals & GPO contracts
More good news from Quotient! Not only do we have FDA-approved Reagent Red Blood Cells products, but also just approved Rare Antisera, including Anti-s and Anti-Wra. We also have new 3-yr agreements with Premier Inc. and the General Services Administration. Great products and value from the one manufacturer focused on manual testing. Contact us today.

  Science & Health 
  • Study: Foam safer than clay in halting open-wound blood flow
    In vitro tests by researchers from the U.S. and Singapore indicated that a silica mesocellular foam was less toxic but performed as well as aluminosilicate-layered clay in promoting blood clotting in open wounds. Foams could be considered as a safer alternative to current hemostatic agents, according to researchers at the University of California, Santa Barbara, and the Institute of Bioengineering and Nanotechnology in Singapore. Royal Society of Chemistry (12/5) LinkedInFacebookTwitterEmail this Story
  • Zinc oxide nanoflowers promote blood vessel growth
    Indian researchers have discovered that flower-shaped nanoparticles of zinc oxide are capable of encouraging the growth of new blood vessels, which could help treat damaged vessels and tissues. The researchers tested the nanoflower method on human umbilical vein endothelial cells and fertilized chicken egg yolks. Studies are planned to assess the potential tumor risk of the blood vessel-promoting agents. Nature/Nature India (12/6) LinkedInFacebookTwitterEmail this Story
  • Hormone disorder plus contraceptive use raises women's clot risk
    The risk of venous thromboembolism was two times higher in women with polycystic ovary syndrome who took oral contraceptives compared with other women who used oral contraceptives. Researchers looked at records from a health insurance database that includes 43,500 women with polycystic ovary syndrome. The study appeared online in the Canadian Medical Association Journal. Reuters (12/3) LinkedInFacebookTwitterEmail this Story
Immucor Announces TPHA Screen: Now FDA Cleared!
Consolidate your donor screening test menu with TPHA Screen on the Galileo® and NEO® automated platforms. Immucor offers the most comprehensive automated donor screening menu to include ABO/Rh, Weak D, Rh/Kell Phenotype, Pooled Antibody Screen, CMV and Syphilis. To learn more please visit our website.

  Industry News & Practice 
  • Academic-industry initiative to focus on stem cells in drug discovery
    Roche Holding and the Innovative Medicines Initiative are establishing StemBANCC, an academic-industry collaboration that aims to use human induced pluripotent stem cells for drug discovery and research. The project will include 10 drugmakers and 23 academic institutions studying the use of human iPS cells for the identification of drug targets and biomarkers and the screening of drug benefits and toxicology. "The aim of StemBANCC is to generate and characterize 1,500 high-quality human induced pluripotent stem cell lines derived from 500 patients that can be used by researchers to study a range of diseases, including diabetes and dementia," project coordinator Martin Graf said. Genetic Engineering & Biotechnology News (12/5), GenomeWeb Daily News (free registration) (12/5) LinkedInFacebookTwitterEmail this Story
Quality and Process Improvement Solutions are Just a Click Away
AABB Consulting Services can help you meet the requirements of any accrediting organization. Guidance is also available for: implementation plans, process flow, software issues, computer validation, compliance audits, vendor audits and custom projects. For more information, visit our web site or email

  Government & Regulatory 
  • FDA appears ready to rethink antibiotic development
    An advisory panel's vote last week is among the signals that the FDA may be ready to reconsider the requirements for the clinical trials of antibiotics. As multidrug-resistant bacteria strains have become more common, new antibiotic approvals have decreased. Nature (12/4) LinkedInFacebookTwitterEmail this Story
  • Lawmaker proposes mobile, wireless health bill
    Rep. Mike Honda, D-Calif., has proposed a bill that would aim to form a mobile health system initiative at HHS and eliminate obstacles to wireless health adoption. The legislation also looks at the development of a tax incentive program that would help providers cut their costs associated with non-EHR health IT activities and calls for the FDA to develop an Office of Wireless Health. Healthcare Informatics online (12/4), (12/4) LinkedInFacebookTwitterEmail this Story
  Association News 
  • AABB Center for Cellular Therapies to develop directory of training programs
    The AABB Center for Cellular Therapies is developing a directory of training programs for cellular therapies. This online tool will index information on training relevant to cellular therapies available through AABB and other institutions — including information such as tuition, application process, length of training and contact details. The association encourages institutions interested in contributing to this educational database to contact the AABB Center for Cellular Therapies. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
West Coast Account ManagerMacopharma USAUS - Nationwide
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Click here to view more job listings.

To change one's life: Start immediately. Do it flamboyantly. No exceptions."
--William James,
American psychologist and philosopher

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
A powerful website for SmartBrief readers including:
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information